Clinically Available Insulins
Modern genetic engineering techniques enable specific amino acids in the molecule to be changed and the molecule subtly altered to form new preparations with advantageous properties for people with diabetes.
Classification of Clinically available Insulin Preparations -
- Rapid Acting: Insulin lispro, Insulin Aspart
- Short Acting: Regular Human insulin
- Intermediate Acting: NPH Human
- Long Acting: Insulin Detemir, Insulin Degludec.
Pharmacokinetics of Insulin preparations:
- Administered via SQ injection and absorbed directly to the systemic circulation
- Majority of insulin degradation happens in the Liver and Kidney
- Kidney is the main metabolism site
- Do not enter the Hepatic portal system.
CLASS |
Onset of
Action |
DOA |
Example |
|
Rapid Acting |
Inhaled |
10 – 30 m |
2-4 hrs |
Afrezza |
Oral |
15 – 30 m |
3 hrs |
Lispro;
Aspart |
|
Short Acting |
30 m – 1 hrs |
15 – 30 m |
Human Insulin
(IV) |
|
Intermediate
Acting |
2 – 4 hrs |
12 – 18 Hrs |
NPH Insulin |
|
Long Acting |
> 4 hrs |
24 Hrs |
Detemir |
|
Ultra Long |
> 5 – 6 Hrs
|
Upto 48 hrs |
Degludec |
|
Premixed Insulin
|
< 30 min |
2 – 4 hrs |
NPH : Regular
(70:30) |
Common Side effects:
- Hypoglycemia
- Injection site reaction
- Weight gain
- Headache
- Lipodystrophy
Comments
Post a Comment